SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.52+0.4%12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robohogs who wrote (21819)11/2/2006 9:41:57 PM
From: rkrw  Read Replies (1) of 52153
 
And it all makes sepr look very good. Had a special dose for elderly, did the longer studies and got approved right away.

Goes to show the pfizer validation isn't always the do all end all. How many people wondered why pfizer partnered with nbix and not sepr? Even Lyons used to imply pfe passed on lunesta. Didn't Lyons say after pfe walked that it would cost just $30M to refile indiplon? What does he say now? :-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News